ASH: MPN with a Focus on Myelofibrosis
This section of the 2023 ASH Annual Meeting focused on the latest developments on myeloproliferative neoplasms with a focus on myelofibrosis.
Advertisement
Advertisement
Venugopal highlights myelofibrosis research at ASH 2023.
CALR and MPL mutations, which are associated with better outcomes, showed earlier mutation clearance than JAK2.
Mass spectrometry–based proteomics were used to learn more about how MKs drive bone marrow fibrosis.
Prevalence of symptoms was assessed with the Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score.
The retrospective study evaluated if pacritinib increased PLT counts in the phase III PERSIST-2 and phase II PAC203 studies.
Responses in hemoglobin, white blood cell, and platelet were 75%, 82%, and 74%, respectively, at 24 weeks.
Multivariable modeling showed a notable reduction in the risk of GVHD or relapse in the ATG group.
Hemoglobin and platelets are correlated with OS, while mutations in ASXL1, EZH2, IDH1/2, U2AF1, and SRSF2 are not.
The model could be helpful in understanding fibrotic progression in JAK2V617F mutation–positive MPNs.
Ruben Mesa, MD, discussed the results at the 65th ASH Annual Meeting and Exposition.
This is just one finding from a longitudinal analysis of phase III data from the SIMPLIFY-1 and MOMENTUM trials.
Review more from the post-hoc time-dependent analysis of the phase III Simplify-1, Simplify-2, and MOMENTUM trials.
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.